Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Dana A. Chitu"'
Autor:
Jacobien R. Hilberink, Isabelle A. van Zeventer, Dana A. Chitu, Thomas Pabst, Saskia K. Klein, Georg Stussi, Laimonas Griskevicius, Peter J. M. Valk, Jacqueline Cloos, Arjan A. van de Loosdrecht, Dimitri Breems, Danielle van Lammeren-Venema, Rinske Boersma, Mojca Jongen-Lavrencic, Martin Fehr, Mels Hoogendoorn, Markus G. Manz, Maaike Söhne, Rien van Marwijk Kooy, Dries Deeren, Marjolein W. M. van der Poel, Marie Cecile Legdeur, Lidwine Tick, Yves Chalandon, Emanuele Ammatuna, Sabine Blum, Bob Löwenberg, Gert J. Ossenkoppele, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), Swiss Group for Clinical Cancer Research (SAKK), Gerwin Huls
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-9 (2023)
Abstract Treatment choice according to the individual conditions remains challenging, particularly in older patients with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS). The impact of performance status, comorbidities, and
Externí odkaz:
https://doaj.org/article/71614de5d82b474e855269ada1ea2dee
Autor:
Rebecca van Grootveld, Valentina Masarotto, Peter A. von dem Borne, Nicole M. A. Blijlevens, Dana A. Chitu, Martha T. van der Beek, Marta Fiocco, Mark G. J. de Boer
Publikováno v:
BMC Infectious Diseases, Vol 23, Iss 1, Pp 1-9 (2023)
Abstract Purpose Study objectives were to estimate the cumulative incidence of death due to different causes of death (CODs) and investigate the effect of invasive aspergillosis (IA) on each separate COD in a cohort of older patients with acute myelo
Externí odkaz:
https://doaj.org/article/519d33cf622c40b4ab878f981e53f901
Autor:
Natasha K.A. van Eijkelenburg, Mareike Rasche, Essam Ghazaly, Michael N. Dworzak, Thomas Klingebiel, Claudia Rossig, Guy Leverger, Jan Stary, Eveline S.J.M. De Bont, Dana A. Chitu, Yves Bertrand, Benoit Brethon, Brigitte Strahm, Inge M. van der Sluis, Gertjan J.L. Kaspers, Dirk Reinhardt, C. Michel Zwaan
Publikováno v:
Haematologica, Vol 103, Iss 9 (2018)
Survival in children with relapsed/refractory acute myeloid leukemia is unsatisfactory. Treatment consists of one course of fludarabine, cytarabine and liposomal daunorubicin, followed by fludarabine and cytarabine and stem-cell transplantation. Stud
Externí odkaz:
https://doaj.org/article/e83b67ad53a44206b03414604c18aca2
Autor:
Eline M.P. Cremers, Theresia M. Westers, Canan Alhan, Claudia Cali, Heleen A. Visser-Wisselaar, Dana A. Chitu, Vincent H.J. van der Velden, Jeroen G. te Marvelde, Saskia K. Klein, Petra Muus, Edo Vellenga, Georgina E. de Greef, Marie-Cecile C.J.C. Legdeur, Pierre W. Wijermans, Marian J.P.L. Stevens-Kroef, Pedro da Silva-Coelho, Joop H. Jansen, Gert J. Ossenkoppele, Arjan A. van de Loosdrecht
Publikováno v:
Haematologica, Vol 102, Iss 2 (2017)
Flow cytometric analysis is a recommended tool in the diagnosis of myelodysplastic syndromes. Current flow cytometric approaches evaluate the (im)mature myelo-/monocytic lineage with a median sensitivity and specificity of ~71% and ~93%, respectively
Externí odkaz:
https://doaj.org/article/ce60285c497d4c0a8b8092e8a4f0c35f
Autor:
Canan Alhan, Arjan A. van de Loosdrecht, Dana A. Chitu, Aniek O. de Graaf, Heleen Visser-Wisselaar, Bianca Venniker-Punt, Linda Smit, Eline M. P. Cremers, Theresia M. Westers, Florentien E. M. in ’t Hout, Joop H. Jansen, Carolien Duetz
Publikováno v:
British Journal of Haematology, 193(4), 798-803. Wiley-Blackwell
British Journal of Haematology
British Journal of Haematology, 193(4), 798-803. Wiley
Duetz, C, Westers, T M, in ’t Hout, F E M, Cremers, E M P, Alhan, C, Venniker-Punt, B, Visser-Wisselaar, H A, Chitu, D A, de Graaf, A O, Smit, L, Jansen, J H & van de Loosdrecht, A A 2021, ' Distinct bone marrow immunophenotypic features define the splicing factor 3B subunit 1 (SF3B1)-mutant myelodysplastic syndromes subtype ', British Journal of Haematology, vol. 193, no. 4, pp. 798-803 . https://doi.org/10.1111/bjh.17414
British Journal of Haematology, 193, 4, pp. 798-803
British Journal of Haematology, 193, 798-803
British Journal of Haematology
British Journal of Haematology, 193(4), 798-803. Wiley
Duetz, C, Westers, T M, in ’t Hout, F E M, Cremers, E M P, Alhan, C, Venniker-Punt, B, Visser-Wisselaar, H A, Chitu, D A, de Graaf, A O, Smit, L, Jansen, J H & van de Loosdrecht, A A 2021, ' Distinct bone marrow immunophenotypic features define the splicing factor 3B subunit 1 (SF3B1)-mutant myelodysplastic syndromes subtype ', British Journal of Haematology, vol. 193, no. 4, pp. 798-803 . https://doi.org/10.1111/bjh.17414
British Journal of Haematology, 193, 4, pp. 798-803
British Journal of Haematology, 193, 798-803
Summary Splicing factor 3B subunit 1 (SF3B1) mutations define a distinct myelodysplastic syndromes (MDS) patient group with a relatively favourable disease course and high response rates to luspatercept. Few data are available on bone marrow phenotyp
Autor:
Mels Hoogendoorn, Rineke B L Leys, Dana A. Chitu, Okke de Weerdt, Hanneke C. Kluin-Nelemans, Eva de Jongh, Rien van Marwijk Kooij, Robby E. Kibbelaar, Mars B. van 't Veer, Michel van Gelder, Monique C. Minnema, Marie Josee Kersten, Josée M. Zijlstra, Daphne de Jong, Jeanette K. Doorduijn, M.A. MacKenzie, Tjeerd J. F. Snijders, Pieternella J. Lugtenburg, Lara H Böhmer
Publikováno v:
Doorduijn, J K, Zijlstra, J M, Lugtenburg, P J, Kersten, M J, Böhmer, L H, Minnema, M C, MacKenzie, M A, van Marwijk Kooij, R, de Jongh, E, Snijders, T J F, de Weerdt, O, van Gelder, M, Hoogendoorn, M, Leys, R B L, Kibbelaar, R E, de Jong, D, Chitu, D A, Van’t Veer, M B & Kluin-Nelemans, H C 2020, ' Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial ', British Journal of Haematology, vol. 190, no. 3, pp. 385-393 . https://doi.org/10.1111/bjh.16567
British Journal of Haematology, 190(3), 385-393. Wiley
British Journal of Haematology, 190(3), 385-393. Wiley-Blackwell
British Journal of Haematology, 190, 3, pp. 385-393
British Journal of Haematology
British Journal of Haematology, 190, 385-393
British Journal of Haematology, 190(3), 385-393. Wiley-Blackwell Publishing Ltd
British journal of haematology, 190(3), 385-393. Wiley-Blackwell
British Journal of Haematology, 190(3), 385-393. Wiley
British Journal of Haematology, 190(3), 385-393. Wiley-Blackwell
British Journal of Haematology, 190, 3, pp. 385-393
British Journal of Haematology
British Journal of Haematology, 190, 385-393
British Journal of Haematology, 190(3), 385-393. Wiley-Blackwell Publishing Ltd
British journal of haematology, 190(3), 385-393. Wiley-Blackwell
Contains fulltext : 225496.pdf (Publisher’s version ) (Open Access) Rituximab-containing induction followed by autologous stem cell transplantation (ASCT) is the standard first-line treatment for young mantle cell lymphoma patients. However, most p
Autor:
Rien van Marwijk Kooy, Gert J. Ossenkoppele, Arjan A. van de Loosdrecht, Wim Terpstra, Dana A. Chitu, Okke de Weerdt, Dimitri Breems, Bob Löwenberg, Jürgen Kuball, Marie-Christiane Vekemans, Edo Vellenga, Dries Deeren, Bart J. Biemond, Gerwin Huls, Saskia K. Klein, Harm Sinnige, Violaine Havelange, Mojca Jongen-Lavrencic, Beata Hodossy, Carlos Graux
Publikováno v:
Blood, 133, 13, pp. 1457-1464
Blood, Vol. 133, no. 13, p. 1457-1464 (2019)
Huls, G, Chitu, D A, Havelange, V, Jongen-Lavrencic, M, van de Loosdrecht, A A, Biemond, B J, Sinnige, H, Hodossy, B, Graux, C, Kooy, R V M, de Weerdt, O, Breems, D, Klein, S, Kuball, J R, Deeren, D, Terpstra, W, Vekemans, M-C, Ossenkoppele, G J, Vellenga, E, Löwenberg, B & Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) 2019, ' Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients ', Blood, vol. 133, no. 13, pp. 1457-1464 . https://doi.org/10.1182/blood-2018-10-879866
Blood, 133(13), 1457-1464. American Society of Hematology
Blood, 133, 1457-1464
Blood, 133(13), 1457-1464. AMER SOC HEMATOLOGY
Blood, 133(13), 1457. American Society of Hematology
Blood, Vol. 133, no. 13, p. 1457-1464 (2019)
Huls, G, Chitu, D A, Havelange, V, Jongen-Lavrencic, M, van de Loosdrecht, A A, Biemond, B J, Sinnige, H, Hodossy, B, Graux, C, Kooy, R V M, de Weerdt, O, Breems, D, Klein, S, Kuball, J R, Deeren, D, Terpstra, W, Vekemans, M-C, Ossenkoppele, G J, Vellenga, E, Löwenberg, B & Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) 2019, ' Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients ', Blood, vol. 133, no. 13, pp. 1457-1464 . https://doi.org/10.1182/blood-2018-10-879866
Blood, 133(13), 1457-1464. American Society of Hematology
Blood, 133, 1457-1464
Blood, 133(13), 1457-1464. AMER SOC HEMATOLOGY
Blood, 133(13), 1457. American Society of Hematology
The prevention of relapse is the major therapeutic challenge in older patients with acute myeloid leukemia (AML) who have obtained a complete remission (CR) on intensive chemotherapy. In this randomized phase 3 study (HOVON97) in older patients (≥6
Autor:
Dana A. Chitu, Canan Alhan, Arjan A. van de Loosdrecht, Heleen Visser-Wisselaar, Theresia M. Westers
Publikováno v:
Westers, T M, Alhan, C, Visser-Wisselaar, H A, Chitu, D A & van de Loosdrecht, A A 2021, ' Dysplasia and PNH-type cells in bone marrow aspirates of myelodysplastic syndromes ', Cytometry Part B-Clinical Cytometry . https://doi.org/10.1002/cyto.b.22038
Cytometry Part B-Clinical Cytometry, 104(2), 162-172. Wiley-Liss Inc.
Cytometry Part B-Clinical Cytometry. Wiley-Liss Inc.
Cytometry Part B-Clinical Cytometry, 104(2), 162-172. Wiley-Liss Inc.
Cytometry Part B-Clinical Cytometry. Wiley-Liss Inc.
Background: Flow cytometry is increasingly applied in cytopenic patients suspected for myelodysplastic syndromes (MDS). Analysis includes evaluation of antigen expression patterns in granulocytes of which, for example, partial lack of CD16 may indica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::582eacc791d99baed6e7e15042ede096
https://research.vumc.nl/en/publications/5d6fca22-6184-4431-bd38-0cc645addda3
https://research.vumc.nl/en/publications/5d6fca22-6184-4431-bd38-0cc645addda3
Autor:
Theresia M. Westers, Joop H. Jansen, Canan Alhan, Costa Bachas, Arjan A. van de Loosdrecht, Sofie Van Gassen, Yvan Saeys, Carolien Duetz, Eline M. P. Cremers, Margot F. van Spronsen, Aniek O. de Graaf, Florentien E. M. in ’t Hout, Dana A. Chitu, Heleen Visser-Wisselaar
Publikováno v:
Blood, 136. American Society of Hematology
Duetz, C, Van Gassen, S, Westers, T M, in 't Hout, F, Cremers, E, Alhan, C, Bachas, C, Van Spronsen, M F, Visser-Wisselaar, H, Chitu, D, De Graaf, A O, Jansen, J, Saeys, Y & van de Loosdrecht, A 2020, ' Machine Learning-Based Flow Cytometry Diagnostics in Myelodysplastic Syndromes: Validation in the HOVON89 Clinical Trial (EudraCT 2008-002195-10) ', Blood, vol. 136 . https://doi.org/10.1182/blood-2020-136719
Duetz, C, Van Gassen, S, Westers, T M, in 't Hout, F, Cremers, E, Alhan, C, Bachas, C, Van Spronsen, M F, Visser-Wisselaar, H, Chitu, D, De Graaf, A O, Jansen, J, Saeys, Y & van de Loosdrecht, A 2020, ' Machine Learning-Based Flow Cytometry Diagnostics in Myelodysplastic Syndromes: Validation in the HOVON89 Clinical Trial (EudraCT 2008-002195-10) ', Blood, vol. 136 . https://doi.org/10.1182/blood-2020-136719
Introduction Flow cytometry is a recommended tool in the diagnostic work-up of cytopenic patients suspected for myelodysplastic syndromes. Currently used flow cytometry scores rely on human assessment of dysplastic features in the bone marrow. Althou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b733e1e6d642fa9160cd22ab22cf568
https://research.vumc.nl/en/publications/258b89fd-5538-42b7-941a-639363db9f3b
https://research.vumc.nl/en/publications/258b89fd-5538-42b7-941a-639363db9f3b
Autor:
Peter J. M. Valk, Yves Chalandon, Thomas Pabst, Markus G. Manz, Dimitri Breems, Maaike Sohne, Bob Löwenberg, Emanuele Ammatuna, Marjolein van der Poel, Sabine Blum, Dries Deeren, Rien van Marwijk Kooy, Dana A. Chitu, Mojca Jongen-Lavrencic, Lidwine W. Tick, Marie Cecile J.C. Legdeur, Gerwin Huls, Saskia K. Klein, Danielle van Lammeren-Venema, Gert J. Ossenkoppele, Georg Stussi, Arjan A. van de Loosdrecht, Isabelle A van Zeventer, Rinske S. Boersma, M. Fehr, Mels Hoogendoorn, Jacqueline Cloos, Laimonas Griskevicius
Publikováno v:
Blood advances, vol. 4, no. 18, pp. 4267-4277
Blood Advances, Vol. 4, No 18 (2020) pp. 4267-4277
Blood, 4(18), 4267-4277. AMER SOC HEMATOLOGY
Blood, 4(18), 4267-4277. American Society of Hematology
Blood advances, 4(18), 4267-4277. American Society of Hematology
Huls, G, Chitu, D A, Pabst, T, Klein, S K, Stussi, G, Griskevicius, L, Valk, P J M, Cloos, J, van de Loosdrecht, A A, Breems, D, van Lammeren-Venema, D, van Zeventer, I, Boersma, R, Jongen-Lavrencic, M, Fehr, M, Hoogendoorn, M, Manz, M G, Söhne, M, Kooy, R V M, Deeren, D, van der Poel, M W M, Legdeur, M C, Tick, L, Chalandon, Y, Ammatuna, E, Blum, S, Löwenberg, B & Ossenkoppele, G J 2020, ' Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS ', Blood, vol. 4, no. 18, pp. 4267-4277 . https://doi.org/10.1182/BLOODADVANCES.2020002846
Blood advances, 4(18), 4267-4277. The American Society of Hematology
Blood Adv
Blood Advances, Vol. 4, No 18 (2020) pp. 4267-4277
Blood, 4(18), 4267-4277. AMER SOC HEMATOLOGY
Blood, 4(18), 4267-4277. American Society of Hematology
Blood advances, 4(18), 4267-4277. American Society of Hematology
Huls, G, Chitu, D A, Pabst, T, Klein, S K, Stussi, G, Griskevicius, L, Valk, P J M, Cloos, J, van de Loosdrecht, A A, Breems, D, van Lammeren-Venema, D, van Zeventer, I, Boersma, R, Jongen-Lavrencic, M, Fehr, M, Hoogendoorn, M, Manz, M G, Söhne, M, Kooy, R V M, Deeren, D, van der Poel, M W M, Legdeur, M C, Tick, L, Chalandon, Y, Ammatuna, E, Blum, S, Löwenberg, B & Ossenkoppele, G J 2020, ' Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS ', Blood, vol. 4, no. 18, pp. 4267-4277 . https://doi.org/10.1182/BLOODADVANCES.2020002846
Blood advances, 4(18), 4267-4277. The American Society of Hematology
Blood Adv
The treatment of older, unfit patients with acute myeloid leukemia (AML) is challenging. Based on preclinical data of Bruton tyrosine kinase expression/phosphorylation and ibrutinib cytotoxicity in AML blasts, we conducted a randomized phase 2 multic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f035f8641df261cae7346abf960dbaaf
https://serval.unil.ch/notice/serval:BIB_BA95A00DDE07
https://serval.unil.ch/notice/serval:BIB_BA95A00DDE07